Lenalidomide Anabiosis

Lenalidomide, the active ingredient in Lenalidomide Anabiosis, is an immunomodulatory imide drug (IMiD) presented as an oral formulation for oral use. It is indicated for the treatment of multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide Anabiosis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with adherence to EU quality standards and regulatory requirements.

Lenalidomide is used in hematologic malignancies that involve abnormal plasma or lymphoid cells. - Multiple Myeloma: improves progression‑free survival and overall response rates in adult patients. - Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. - Mantle Cell Lymphoma: provides disease control in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Fatigue: persistent tiredness. - Diarrhea: loose stools. - Nausea: upset stomach. - Rash: skin redness or itching. Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly reduced neutrophil count. - Secondary primary malignancies: emergence of new cancers.

When prescribing Lenalidomide Anabiosis, consider the following precautions. - Dose adjustment in renal impairment: evaluate kidney function before prescribing. - Monitor blood counts regularly: check CBC to detect cytopenias. - Assess thrombotic risk: consider prophylactic anticoagulation in high‑risk patients. - Avoid use in pregnancy: teratogenic risk requires strict contraception. - Pregnancy testing: perform before initiating therapy and periodically thereafter. - Store at ambient temperature: keep below 25°C in original packaging, protect from moisture.

Lenalidomide may interact with several medicines; awareness of major and moderate interactions helps manage risk. Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin, DOACs): increased risk of thrombosis or bleeding. - Immunosuppressants (e.g., cyclosporine): may enhance hematologic toxicity. Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase lenalidomide levels. - Live attenuated vaccines: reduced efficacy, consider timing. - NSAIDs: may exacerbate thrombocytopenia.